220 related articles for article (PubMed ID: 30255380)
21. Carboplatin hypersensitivity: evaluation and successful desensitization protocol.
Bruchim I; Goldberg A; Fishman A; Confino-Cohen R
Immunotherapy; 2014; 6(8):905-12. PubMed ID: 25313569
[TBL] [Abstract][Full Text] [Related]
22. A new non-dilution rapid desensitization protocol successfully applied to all-grade platinum hypersensitivity.
Chung SJ; Kang SY; Kang RY; Kim YC; Lee KH; Kim TY; Han SW; Kang HR
Cancer Chemother Pharmacol; 2018 Nov; 82(5):777-785. PubMed ID: 30105458
[TBL] [Abstract][Full Text] [Related]
23. Oxaliplatin-induced hypersensitivity reactions: risk factors and management.
Selcuk A; Yıldız B
Eur Rev Med Pharmacol Sci; 2023 Mar; 27(6):2640-2645. PubMed ID: 37013782
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of Therapeutic Plasma Exchange in Severe Immune Hemolytic Anemia Induced by a Carboplatin Desensitization Procedure.
Vilà-Nadal G; Fiandor Román A; Heredia Revuelto R; Hernández-Maraver D; Kerguelen Fuentes AE; Ramírez García E; Cabañas Moreno R
J Investig Allergol Clin Immunol; 2021 Apr; 31(2):178-179. PubMed ID: 32732185
[No Abstract] [Full Text] [Related]
25. Complete metabolic response after carboplatin desensitization in Peritoneal Carcinomatosis.
Villarreal-González RV; González-Díaz SN; Vidal-Gutiérrez O; Zayas-Villanueva OA; Solís-Lara H; Santos-Fernández WJ; Casas-Murillo CA; López-Méndez A
J Oncol Pharm Pract; 2022 Sep; 28(6):1441-1445. PubMed ID: 35119322
[TBL] [Abstract][Full Text] [Related]
26. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
27. A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian Cancer.
LaVigne K; Hyman DM; Zhou QC; Iasonos A; Tew WP; Aghajanian C; Makker V; Hensley ML; Konner J; Grisham RN; Cangemi N; Soldan K; Spriggs DR; Sabbatini PJ; OʼCearbhaill RE
Int J Gynecol Cancer; 2018 Jul; 28(6):1176-1182. PubMed ID: 29757876
[TBL] [Abstract][Full Text] [Related]
28. Hypersensitivity Reactions to Oxaliplatin: Identifying the Risk Factors and Judging the Efficacy of a Desensitization Protocol.
Okayama T; Ishikawa T; Sugatani K; Yoshida N; Kokura S; Matsuda K; Tsukamoto S; Ihara N; Kuriu Y; Nakanishi M; Nakamura T; Kamada K; Katada K; Uchiyama K; Takagi T; Handa O; Konishi H; Yagi N; Naito Y; Otsuji E; Hosoi H; Miki T; Itoh Y
Clin Ther; 2015 Jun; 37(6):1259-69. PubMed ID: 25862137
[TBL] [Abstract][Full Text] [Related]
29. Desensitization strategy for hypersensitivity reactions to carboplatin in five patients with gynecological cancer.
Toyohara Y; Sone K; Nishida H; Taguchi A; Miyamoto Y; Tanikawa M; Mori M; Tsuruga T; Matsumoto Y; Oda K; Osuga Y; Fujii T
J Obstet Gynaecol Res; 2020 Nov; 46(11):2298-2304. PubMed ID: 32830407
[TBL] [Abstract][Full Text] [Related]
30. [Successful desensitization protocol for patients with hypersensitivity reactions caused by carboplatin].
Nishio S; Koyanagi T; Miyabe K; Kuromatsu H
Gan To Kagaku Ryoho; 2010 Apr; 37(4):731-3. PubMed ID: 20414037
[TBL] [Abstract][Full Text] [Related]
31. Incidence of Carboplatin-related hypersensitivity reactions in Japanese patients with gynecologic malignancies.
Koshiba H; Hosokawa K; Kubo A; Miyagi Y; Oda T; Miyagi Y; Watanabe A; Honjo H
Int J Gynecol Cancer; 2009 Apr; 19(3):460-5. PubMed ID: 19407575
[TBL] [Abstract][Full Text] [Related]
32. Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity.
Rose PG; Fusco N; Smrekar M; Mossbruger K; Rodriguez M
Gynecol Oncol; 2003 Jun; 89(3):429-33. PubMed ID: 12798707
[TBL] [Abstract][Full Text] [Related]
33. The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment.
O'Cearbhaill R; Zhou Q; Iasonos A; Hensley ML; Tew WP; Aghajanian C; Spriggs DR; Lichtman SM; Sabbatini PJ
Gynecol Oncol; 2010 Mar; 116(3):326-31. PubMed ID: 19944454
[TBL] [Abstract][Full Text] [Related]
34. Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions.
Markman M; Hsieh F; Zanotti K; Webster K; Peterson G; Kulp B; Spicel A; Belinson J
J Cancer Res Clin Oncol; 2004 Jan; 130(1):25-8. PubMed ID: 14564516
[TBL] [Abstract][Full Text] [Related]
35. Management of hypersensitivity reactions to Carboplatin and Paclitaxel in an outpatient oncology infusion center: a 5-year review.
Banerji A; Lax T; Guyer A; Hurwitz S; Camargo CA; Long AA
J Allergy Clin Immunol Pract; 2014; 2(4):428-33. PubMed ID: 25017531
[TBL] [Abstract][Full Text] [Related]
36. Prevention of carboplatin-induced hypersensitivity reactions in women with ovarian cancer.
Jerzak KJ; Deghan Manshadi S; Ng P; Maganti M; McCuaig JM; Bulter M; Oza A; Mackay HJ
J Oncol Pharm Pract; 2018 Mar; 24(2):83-90. PubMed ID: 27856924
[TBL] [Abstract][Full Text] [Related]
37. BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer - an observational cohort study.
Unni SK; Schauerhamer MB; Deka R; Tyczynski JE; Fernandes AW; Stevens V; Brixner DI; Stenehjem DD
J Ovarian Res; 2016 Mar; 9():18. PubMed ID: 27004793
[TBL] [Abstract][Full Text] [Related]
38. Platin desensitizations in thoracic malignancies and risk factors for breakthrough reactions.
Buhari GK; Kalkan İK; Ateş H; Bahçecioğlu SN; Demir Ş; Yeşilkaya S; Solak GTV; Aksu K; Erkekol FÖ
Allergol Immunopathol (Madr); 2023; 51(2):130-136. PubMed ID: 36916098
[TBL] [Abstract][Full Text] [Related]
39. Carboplatin Hypersensitivity Reactions in Pediatric Low Grade Glioma Are Protocol Specific and Desensitization Shows Poor Efficacy.
Dodgshun AJ; Hansford JR; Cole T; Choo S; Sullivan MJ
Pediatr Blood Cancer; 2016 Jan; 63(1):17-20. PubMed ID: 26207610
[TBL] [Abstract][Full Text] [Related]
40. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions.
Lee CW; Matulonis UA; Castells MC
Gynecol Oncol; 2004 Nov; 95(2):370-6. PubMed ID: 15491759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]